Deals In Depth: March 2014
Executive Summary
In a deal worth $139 million, UCB and Sanofi are pursuing anti-inflammatory medications for GI conditions and arthritis; Sterigenics bought isotope maker Nordion for $727 million. Public offerings again drove biopharma financing, making up more than 50% of the $3.4 billion raised; device financing totaled $219 million, with most of the funding from debt and FOPO transactions.
You may also be interested in...
Keeping Track: Tumor-Agnostic Approval For Novartis; Submissions From Krystal, Menarini, And Astellas
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Allowing States To Ban Abortion Services Increases Calls For Making Birth Control Available OTC
Supreme Court’s six conservative justices say Constitution doesn’t guarantee a woman’s right to abortion services nor prohibit states from regulating or banning the services. Dissenting liberal members decry decision as erasing women’s constitutional rights.
RSV Vaccine May Be On Market In 2023, CDC’s ACIP Anticipates
Panel expects to review five respiratory syncytial virus vaccines and vote on one or two of them in June 2023 and others four months later. Sanofi presents results of three clinical trials of its monoclonal antibody nirsevimab, which is on track to be the second RSV prophylaxis for infants.